^
Association details:
| Biomarker: | MDM2 amplification + CDK4 amplification |
|---|---|
| Cancer: | Liposarcoma |
| Drug: | Istodax (romidepsin) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
Published date:
10/24/2021
Excerpt:
Among the genes with CNAs, MDM2 and CDK4 were co-amplified...In addition to the co-amplification of MDM2 and CDK4, multiple gene amplifications were observed in chromosome 12q13-15 of the NCC-DDLPS4-C1 cell line...the HDAC inhibitor romidepsin showed equivalent to superior antiproliferative effects on NCC-DDLPS4-C1 cells....We also found that the HDAC inhibitor romidepsin has a remarkable antiproliferative effect on NCC-DDLPS4-C1 cells.
DOI:
https://doi.org/10.3390/jpm11111075
